Trial Profile
Safety, Tolerability and Pharmacokinetics of S 95010 After Single Escalating Intravenous Doses in Young Healthy Male Subjects. A Randomised, Doubleblind, Placebo-controlled, Monocentre, First-In-Human Study
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Feb 2022
Price :
$35
*
At a glance
- Drugs MRG-110 (Primary)
- Indications Heart failure; Ischaemia
- Focus Adverse reactions; First in man
- Sponsors Servier; Viridian Therapeutics
- 28 Jul 2020 According to a miRagen Therapeutics media release, Work reported in the peer-reviewed journal Nucleic Acid Therapeutics was the result of a collaboration between Goethe University, University Hospital Frankfurt, miRagen Therapeutics and Les Laboratories Servier. Financial support for the studies was also provided by the German Centre for Cardiovascular Research (DZHK).
- 28 Jul 2020 According to a miRagen Therapeutics media release, preliminary results from the study, has been published in the peer-reviewed journal Nucleic Acid Therapeutics.
- 28 Jul 2020 Preliminary study results presented in a miRagen Therapeutics media release.